Today: 15 June 2026
Browse Category

NASDAQ:ADPT 19 August 2025 - 6 February 2026

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies shares climbed 6.5% to $17.15 by midday Wednesday, outpacing broader market gains. Biotech ETFs rose about 2.5%. A Form 4 showed Chief People Officer Francis Lo sold 3,125 shares on Jan. 2 under a prearranged 10b5-1 plan, after exercising options. The company is set to present at the J.P. Morgan Healthcare Conference on Jan. 12.
7 January 2026
··
Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open

Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open

Pfizer shares closed Monday at $26.43, up 2.24%, then slipped to $26.34 after hours. Investors are awaiting Tuesday’s analyst call, where management is set to outline 2026 guidance. The company announced a new autoimmune research deal with Adaptive Biotechnologies, worth up to $890 million in milestones. Trading volume was about 60 million shares, below average.
16 December 2025
···
Biggest Stock Losers Today (December 5, 2025): Parsons, Adaptive Biotechnologies, SentinelOne, SoFi and More Slide Despite Calm Markets

Biggest Stock Losers Today (December 5, 2025): Parsons, Adaptive Biotechnologies, SentinelOne, SoFi and More Slide Despite Calm Markets

The S&P 500 closed at 6,870.40, up 0.19% Friday, while Bitcoin fell 3% to just under $89,300. Parsons plunged 21% after losing a key FAA contract; other steep U.S. decliners included Adaptive Biotechnologies, SentinelOne, and several Brazilian financials. Brazil’s Bovespa index dropped 4% after Jair Bolsonaro endorsed his son for president, sending the real down 3%.
6 December 2025
··········
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Genentech is ending its $2 billion cell therapy partnership with Adaptive Biotechnologies, citing cost-cutting but no safety issues. Kriya Therapeutics raised $313 million in Series D funding, one of the year’s largest biotech rounds. The FDA delayed Neurizon’s ALS drug trial review until October due to staffing shortages. Stealth BioTherapeutics has resubmitted its elamipretide application for Barth syndrome after two FDA rejections.
19 August 2025
····

Stock Market Today

  • PepsiCo Launches 'House of Treats' and Supports Regenerative Farming Pilot
    June 15, 2026, 4:33 AM EDT. PepsiCo has introduced its "House of Treats" beverage platform targeting cinemas, stadiums, and live events across the U.K., Poland, Romania, and the Czech Republic. The platform offers personalized drink options such as Yuzu Lychee and White Peach Sangria, aiming to enhance customer experience with shorter lines. Simultaneously, PepsiCo is backing a regenerative farming pilot with RegenLend and Compeer Financial, offering leasing support for strip-till equipment that promotes soil health and reduces costs. This dual strategy advances PepsiCo's sustainability goals and supply chain resilience, aligning beverage innovation with agricultural sustainability.

Latest articles

PepsiCo expands farming work, partners with House of Treats for personalized drinks

PepsiCo expands farming work, partners with House of Treats for personalized drinks

15 June 2026
PepsiCo launches its “House of Treats” customizable beverage platform for cinemas, stadiums, restaurants, and live events in the U.K., Poland, Romania, and the Czech Republic this June, while also piloting a strip-till equipment leasing program for farmers, signaling a dual push into experiential drinks and regenerative agriculture.
Meta Adjusts AI Plans, Zuckerberg Says Missteps Followed Staff Pushback

Meta Adjusts AI Plans, Zuckerberg Says Missteps Followed Staff Pushback

15 June 2026
Meta CEO Mark Zuckerberg admitted mistakes in the company’s rapid AI workforce overhaul as internal tensions rise, but Meta is still ramping up AI investment with 2026 capital expenditures now forecast at $125–$145 billion, up from previous guidance, citing higher component prices and data center costs.
Go toTop